Tradestie Institutional Equity Comparison Engine
PACB vs BMRA โ Head-to-Head Terminal
6-dimension institutional benchmarking across valuation, multi-year operating margins, normalized momentum, and dealer gamma corridors.
Pillar 1 Executive Scorecard & Category Winner Tally
BMRA Overall Edge
BMRA Captures Institutional Edge (2โ1 Pillars ยท 4โ4 Matrix Metrics)
Tradestie Institutional Equity Comparison Engine assigns the overall head-to-head edge to Biomerica Inc (BMRA) driven by superior Growth & Margin, Options & Structure while PACB counters with relative strength in Momentum & Technical. Fundamentally, PACB trades at N/M Forward P/E with -333.0% operating margin (+5.5% YoY revenue) versus BMRA at N/M Forward P/E and -125.2% operating margin (-8.3% YoY). In options structure, PACB sits in BREAKDOWN (47th %ile IV; Dealer Gamma Walls on Pro) against BMRA sits in UNCLASSIFIED (N/A IV; Dealer Gamma Walls on Pro).
Valuation Winner
Tie
PACB N/M vs BMRA N/M Fwd P/E
Growth & Margin Winner
BMRA
Op Margin -333.0% vs -125.2% ยท YoY +5.5% vs -8.3%
Momentum & Technical Winner
PACB
1Y +15.0% vs -46.9% ยท 52W Pos 34% vs 4%
Options & Structure Winner
BMRA
BREAKDOWN (47th %ile IV) vs UNCLASSIFIED (N/A IV)
PACB
NASDAQ
Pacific Biosciences of California, Inc.
Laboratory Analytical Instruments
$1.88
-4.34% 1D
Market Cap
$615.1M
1M Return
+8.38%
1Y Return
+15.03%
Forward P/E
N/M
Unified AI Score
42.0 / 100
HOLD
Tech 15.0
Fund 36.0
Flow 57.0
Mom 40.0
BMRA
NASDAQ
Biomerica Inc
In Vitro & In Vivo Diagnostic Substances
$1.33
-2.32% 1D
Market Cap
$6.0M
1M Return
-28.19%
1Y Return
-46.86%
Forward P/E
N/M
Unified AI Score
44.5 / 100
HOLD
Tech 40.0
Fund 47.0
Flow 50.0
Mom 44.0
Pillar 2 Normalized Relative Return Performance (% Indexed to 0%)
1Y Indexed Return:
PACB +15.03%
BMRA -46.86%
Spread: +61.89 pp (PACB Lead)
Pillar 3 Multi-Year Annual Revenue & Operating Margin Trajectory (USD)
| Period | PACB Revenue | BMRA Revenue | PACB Op. Margin | BMRA Op. Margin | Margin Edge |
|---|---|---|---|---|---|
| FY2019 | $90M | $10M | -110.6% | -46.4% | BMRA |
| FY2020 | $80M | $10M | -132.3% | -41.0% | BMRA |
| FY2021 | $130M | $10M | -161.2% | -104.2% | BMRA |
| FY2022 | $130M | $20M | -239.4% | -24.0% | BMRA |
| FY2023 | $200M | $10M | -166.8% | -135.3% | BMRA |
| FY2024 | $150M | $10M | -308.0% | -117.6% | BMRA |
| FY2025 | $160M | $10M | -346.2% | -96.7% | BMRA |
| FY2026 | N/A | $0M | N/A | -119.5% | BMRA |
Pillar 4 Head-to-Head Fundamental & Valuation Matrix
| Institutional Metric | PACB | BMRA | Criterion | Row Winner |
|---|---|---|---|---|
| Market Capitalization Scale | $615.1M | $6.0M | Larger Scale | PACB |
| Trailing P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Forward P/E Ratio Valuation | N/M | N/M | Lower Multiple | Tie |
| Revenue Growth (YoY) Growth | +5.5% | -8.3% | Higher Growth | PACB |
| Operating Margin (TTM) Profitability | -333.0% | -125.2% | Higher Margin | BMRA |
| Net Profit Margin Profitability | -81.3% | -115.5% | Higher Margin | PACB |
| Return on Equity (ROE) Capital Efficiency | -929.3% | -113.8% | Higher ROE | BMRA |
| 52-Week Range Position Momentum | 34% ($1โ$3) | 4% ($1โ$3) | Stronger Trend | PACB |
| Beta / 30D Volatility Risk Regime | 2.24ฮฒ ยท 110% Vol | 0.67ฮฒ ยท 62% Vol | Lower Realized Risk | BMRA |
| Unified Institutional Score Composite Signal | 42.0 / 100 (HOLD) | 44.5 / 100 (HOLD) | Higher Composite | BMRA |
Pillar 5 Options Structure, IV Regime & Dealer Gamma Corridor
Full PACB vs BMRA Buy Guide
PACB
BREAKDOWN
12d in phase ยท OBV DISTRIBUTION
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
47th %ile
IV Regime
Balanced (25thโ60th %ile)
BMRA
UNCLASSIFIED
0d in phase ยท OBV NEUTRAL
Put Wall Floor
Pro Only
Call Wall Magnet
Pro Only
IV Percentile
N/A
IV Regime
Unclassified
Pillar 6 90-Day Technical & R&D Innovation Disclosures
Corporate R&D & Foundry Tracker
Neither PACB nor BMRA registered frontier semiconductor/AI engineering publications in the trailing 90-day window; head-to-head edge is anchored on operating margin trajectory, valuation multiples, and options structure above.